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The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare
systems in affected communities. Older patients and those with pre-existing medical conditions
have been identified as populations at risk of a severe disease course. It remains unclear at this
point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of
appropriate studies. However, patients with advanced liver disease and those after liver trans-
plantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe
course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare
resources which may negatively impact the care of patients with chronic liver disease that continue
to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedi-
cine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the
virus to patients and healthcare providers, and at the same time maintain standard care for patients
who require immediate medical attention.
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Coronavirus disease 2019 (COVID-19) is caused by
the recently identified coronavirus, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2).
Symptoms associated with COVID-19 are mostly
fever, tiredness and dry cough. Some patients also
develop symptoms including shortness of breath,
aches, nasal congestion, sore throat, anosmia
and ageusia. Nausea, vomiting and diarrhoea occur
less frequently.1 While symptoms remain mild
throughout the course of infection in themajority of
patients, older patients were identified to be at
higher risk of a fatal disease course, with hyper-
tension, diabetes and coronary heart disease being
the most frequent comorbidities in these cohorts.2,3Individualised InfectionMedicine
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(T. Berg)COVID-19 and the liver
While pre-existing liver disease is not specifically
listed in the published cohort studies, elevated
alanine aminotransferase (ALT) levels, reduced
platelet counts and reduced albumin levels at the
time of admission have been associated with
higher mortality,2 although not all of these alter-
ations are independent risk factors. It remains un-
clear at this time whether these laboratory test
alterations are a sign for pre-existing liver diseases
in patients with a more severe course of infection,
whether they rather reflect liver damage caused by
the virus itself, or whether they mirror a severe
inflammatory response (hypoalbuminemia) withdisseminated intravascular coagulation (thrombo-
cytopenia). Possibly, patients with advanced
chronic liver disease are at increased risk of infec-
tion due to cirrhosis-associated immune dysfunc-
tion.4 The same could be true for patients after liver
transplantation and possibly those with autoim-
mune liver diseases who receive immunosuppres-
sive therapies.
However, currently, there are only limited data
available linking underlying liver diseases with the
course of SARS-CoV-2 infection and there are many
open questions (Box 1). Chronic hepatitis B virus
infection for example, which is more prevalent in
China than Europe, does not appear to affect the
outcome of COVID-19.1 In addition, although there
is no proof for this assumption, immunosuppres-
sion may even provide some protection from
immunopathology, which appears to contribute to
lung damage in cases with more severe manifes-
tations of the disease.5,6 These may be associated
with a macrophage activation syndrome in the
context of a hyperinflammatory syndrome charac-
terised by a cytokine storm with multi-organ fail-
ure.7 On the other hand, systemic viral infections
are often associated with transient elevations of
transaminases which may reflect general immune
activation or inflammation caused by circulating
cytokines without compromising liver function, a
phenomenon called “bystander hepatitis”. This
may also be the case in patients with COVID-19
Box 1. Open questions for liver-related basic/translational research
regarding COVID-19.
•  Hepatobiliary and gastrointestinal tracts as a hub for viral trafficking via 
   liver and biliary excretion into the gastrointestinal tract
•  Influence of immunosuppression on course of COVID-19
•  Cirrhosis-associated immune dysfunction and emergence of protective 
   immunity
•  Innate and adaptive immune activation or exhaustion in COVID-19 and 
   their impact on chronic liver disease
•  Risk of SARS-CoV-2 induced hepatic decompensation/ACLF or graft 
   rejection
ACLF, acute-on-chronic liver failure; COVID-19, coronavirus disease 2019;
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Reviewwhere liver failure has not been specifically reported, even in the
most severe and fatal courses of disease.1,2 However, signs of
liver dysfunction may occur in critically ill patients with COVID-
19,8 as reviewed in.9,10 Whether patients with cirrhosis and
COVID-19 are at increased risk of decompensation or develop-
ment of acute-on-chronic liver failure (ACLF), as has been shown
for influenza infection,11 remains to be determined. SARS-CoV-2
may also directly infect liver cells as the receptor of the virus,
angiotensin-converting enzyme 2 (ACE2),12 has been shown to
be expressed on cholangiocytes,13,14 which may explain cases of
viral shedding into the faeces.15,16 How far observations from
Asian cohorts can be transferred to European populations re-
mains to be determined, but it appears unlikely that SARS-CoV-2
infection causes liver damage to an amount that substantially
contributes to the overall disease burden.
Aside from the direct implications of liver disease on the
course of COVID-19 or vice versa, there are several additional
aspects that require attention. The current pandemic and the
amount of available information – including misinformation and
rumours – result in uncertainties and concerns among patients
but also healthcare providers. While the threat that COVID-19
poses should not be underestimated, it remains important to
maintain care of patients with chronic liver disease and to
identify potential ways to prioritise care of these patients in
times of limited healthcare resources.Considerations for patients with chronic liver disease
and patients after liver transplantation
The recommendations provided here address the specific char-
acteristics of patients with liver disease and are meant to provide
additional guidance for the care of these patients. General rec-
ommendations and guidelines with regards to prevention,
diagnosis and treatment of COVID-19 from local authorities
should be adhered to.Outpatient care
The management and surveillance of patients with advanced
liver disease and those receiving immunosuppressive treatment
is often performed in larger units or centres. These institutions,
however, are currently also COVID-19 hotspots, thus, potentially
putting outpatients with chronic liver diseases at risk of noso-
comial infections. In addition, hospital staffs face challenges such
as long working hours and even reduced staffing because ofJHEP Reports 2020COVID-19 quarantining. Therefore, several factors have to be
considered by hepatologists who provide care for these vulner-
able patients. Clearly, prioritisation criteria need to be defined for
outpatient contacts. The general and specific recommendations
provided here (Fig. 1) cannot comprehensively cover all patient
cohorts and are not backed up by datasets. Moreover, the precise
management of these patients strongly depends on the local
COVID-19 burden. In case of COVID-19 in patients with more
advanced chronic liver disease, we recommend admission for
inpatient care depending on the presence of certain risk factors,
which is discussed in more detail in a separate section.Reduction of direct exposure
Physical distancing has been suggested and/or officially imple-
mented in multiple countries across the globe to prevent
dissemination of SARS-CoV-2. This measure aims to prevent a
rapid increase in SARS-CoV-2 infections in the general popula-
tion with the overall goal of minimising the number of patients
with a severe course of COVID-19 at any one time, enabling
healthcare providers to maintain medical/intensive care of these
patients. At the same time, vulnerable patient cohorts should be
protected from individuals with potential SARS-CoV-2 exposure
or infection. Thus, in these patients, the benefits of maintaining
patient care have to be weighed against the risk of infection.
These considerations require adaption of standard operating
procedures for outpatient care, including remodelling of waiting
areas to allow sufficient distance between patients, reduction of
waiting times and encouraging patients to wait outside wherever
possible and eventually be contacted by phone. In addition,
exposure to medical staff should be minimised wherever
possible.
Face-to-face contact is the basis for the physician-patient re-
lationships and allows physicians to quickly assess the overall
condition of the patient. However, due to the amount of indi-
vidual contacts, physicians are at risk of infection and subse-
quently also dissemination of the virus. Thus, it seems
appropriate to also limit the amount of face-to-face contacts for
patients at risk of a more severe course of infection. Technical
solutions are available to enable remote physician-patient in-
teractions and their benefits have already been discussed in the
context of the COVID-19 pandemic.17 Health authorities should
be urged to equip hospitals with such systems not only to attend
to COVID-19 patients who stay in quarantine at home but also to
care for patients that need to be protected from a potentially
harmful infection and guide them through the pandemic,
explaining the future treatment/management strategies/plan
and provide advice concerning general prevention measures.
The current pandemic clearly underlines the importance of
making these technical solutions available to health care pro-
viders in order to be better prepared for situations like these in
the future.Patients with compensated liver disease
General considerations
 Visits to specialised centres can be postponed.
 Use telemedicine or visits by phone wherever possible.
 Routine laboratory testing can be performed locally, e.g.
through primary care physician, and its frequency needs
careful individual risk-benefit considerations.2vol. 2 j 100113
Patients with chronic liver disease  
(including compensated cirrhosis)
Patients with decompensated liver disease   
(including hepatocelullar carcinoma)
Patients with hepatocellular carcinoma
All patients with chronic liver disease should adhere to common rules of physical distancing
Patients after liver transplantation
•  Care should be maintained according to guidelines
•  Minimal exposure to medical staff, by using 
telemedicine/visits by phone wherever possible/re-
quired to avoid admission  
•  Listing for transplantation should be restricted to 
patients with poor short-term prognosis, as 
transplantation activities/organ donations will likely 
be reduced in many countries and areas
•  Reducing the in-hospital liver transplant evaluation 
program to the strictly necessary is recommended 
to shorten hospital stays
•  Emphasis on the importance of vaccination for 
Streptococcus pneumoniae and influenza
•  Guidelines on prophylaxis of spontaneous 
bacterial peritonitis and hepatic encephalopathy 
should be closely followed to avoid admission
•  Include testing for SARS-CoV-2 in patients with 
acute decompensation or acute-on-chronic liver 
failure
•  Maintain care according to guidelines
•  Minimal exposure to medical staff, by using 
telemedicine/visits by phone wherever 
possible/required to avoid admission 
•  Emphasis on the importance of vaccination 
for Streptococcus pneumoniae and 
influenza
•  In stable patients, perform local lab testing 
(including drug levels)
•  We currently advise against reducing 
immunosuppressive therapy. Reduction 
should only be considered under special 
circumstances after consultation with a 
specialist 
•  Care should be maintained according to 
guidelines, including continuing systemic 
treatments and evaluation for liver 
transplantation
•  Minimal exposure to medical staff, by using 
telemedicine/visits by phone wherever 
possible/required to avoid admission
•  In case of COVID-19, early admission is 
recommended. See also section on 
“Inpatient care” 
•  Visits to specialized centres can be postponed
•  Routine laboratory testing can be performed 
locally/off-site 
•  Use telemedicine/visits by phone wherever 
possible
Specific considerations for
Patients with viral hepatitis:
•  No increased risk of a severe course of 
COVID-19 
•  Send follow-up prescriptions for patients on 
antiviral therapy by mail
Patients with NAFLD or NASH:
•  May suffer from diabetes, hypertension and 
obesity, putting them at increased risk of a 
severe course of COVID-19
Patients with autoimmune liver disease: 
•  We currently advise against reducing 
immunosuppressive therapy. Reduction should 
only be considered under special circumstances 
after consultation with a specialist
•  Emphasis on the importance of vaccination for 
Streptococcus pneumoniae and influenza 
Patients with compensated cirrhosis:
•  Consider delaying hepatocelullar carcinoma) 
surveillance and screening for varices. 
Individualized and non-invasive risk assessment 
should be applied for stratification (see also 
section on “Liver-related diagnostic procedures”)
Specific considerations for
Patients actively listed for transplantation: 
•  SARS-CoV-2 routine testing should be performed 
before transplantation in both donors and 
recipients, acknowledging that negative testing 
cannot completely rule out infection.
•  Consent for diagnostic and therapeutic procedures 
related to transplantation should include the 
potential risk for nosocomial COVID-19
•  Living-donor transplantations should be considered 
on a case-by-case basis.
Fig. 1. Flow chart for the prioritisation of patient care in patients with chronic liver disease. The individual management of these patients strongly depends
on the local COVID-19 burden and officially implemented rules and regulations. In some countries and areas, maintenance of standard care might not be able and
transplantation activities might be reduced. COVID-19, coronavirus disease 2019; HCC, hepatocellular carcinoma; NAFLD, non-alcoholic fatty liver disease; NASH,
non-alcoholic steatohepatitis; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.Specific considerations
 Chronic viral hepatitis does not appear to increase the risk of
a severe course of COVID-19.1 Use telemedicine/local labo-
ratory testing for follow-up visits in patients under antiviral
therapy, send follow-up-prescriptions by mail.
 Patients with non-alcoholic fatty liver disease (NAFLD) or
steatohepatitis (NASH) may suffer from metabolic comor-
bidities such as diabetes, hypertension and obesity putting
them at increased risk of a severe course of COVID-19.
 In patients with autoimmune liver disease, we currently
advise against reducing immunosuppressive therapy. Re-
ductions should only be considered under special circum-
stances (e.g. medication-induced lymphopenia, or bacterial/
fungal superinfection in case of severe COVID-19) after
consultation of a specialist.
 Emphasis on the importance of vaccination for Streptococcus
pneumoniae and influenza.
 In patients with compensated cirrhosis, consider delaying
hepatocellular carcinoma (HCC) surveillance and screening
for varices. Non-invasive risk assessment for the presence of
varices should be applied for stratification (thrombocyte
count or Baveno VI).18 See also section on “liver-related
diagnostic procedures”.JHEP Reports 2020Patients with decompensated liver disease
General considerations
 Care should be maintained according to guidelines but
consider minimal exposure to medical staff, by using tele-
medicine/visits by phone wherever possible/required to
avoid admission.
 Listing for transplantation should be restricted to pa-
tients with poor short-term prognosis including those
with acute/acute-on-chronic liver failure (ALF/ACLF), high
model for end-stage liver disease (MELD) score
(including exceptional MELDs) and HCC at the upper
limits of the Milan criteria, as transplantation activities/
organ donations will likely be reduced in many countries
and areas.
 Reducing the in-hospital liver transplant evaluation program
to the strictly necessary is recommended to shorten the in-
hospital stay and also reduce the number of consultations
in other departments/clinics (i.e. ophthalmologic, dermato-
logic, dental, neurologic consultations can be done in local
outpatient settings).
 Emphasis on the importance of vaccination for Streptococcus
pneumoniae and influenza.3vol. 2 j 100113
Review Guidelines on prophylaxis of spontaneous bacterial perito-
nitis and hepatic encephalopathy should be closely followed
to prevent decompensation and avoid admission.
 Include testing for SARS-CoV-2 in patients with acute
decompensation or ACLF.
Specific considerations for patients actively listed for
transplantation
 SARS-CoV-2 routine testing should be performed before
transplantation in both donors and recipients, acknowl-
edging that negative testing cannot completely rule out
infection.
 Consent for diagnostic and therapeutic procedures related
to transplantation should include the potential risk of
nosocomial COVID-19.
 Living-donor transplantations should be considered on a
case-by-case basis.
Patients with hepatocellular carcinoma
 Care should be maintained according to guidelines including
continuing systemic treatments and evaluation for liver
transplantation, but consider minimal exposure to medical
staff, by using telemedicine/visits by phone wherever
possible/required to avoid admission.
 In case of COVID-19, early admission is recommended. See
also section on “inpatient care”.
Patients after liver transplantation
 Maintain care according to guidelines, but consider minimal
exposure to medical staff, by using telemedicine/visits by
phone wherever possible/required to avoid admission.
 Emphasis on the importance of vaccination for Streptococcus
pneumoniae and influenza.
 In stable patients: perform local laboratory testing (including
drug levels).
 We currently advise against reduction of immunosuppres-
sive therapy. Reduction should only be considered under
special circumstances (e.g. medication-induced lymphope-
nia, or bacterial/fungal superinfection in case of severe
COVID-19) after consultation of a specialist.19
Liver-related diagnostic procedures
Endoscopy
Patients without COVID-19: Depending on available resources,
screening for varices by esophagogastroduodenoscopy (EGD)
should be reserved for patients at risk of variceal bleeding, such
as patients with a history of variceal bleeding or signs of sig-
nificant portal hypertension (ascites, thrombocyte count
<100,000/ll). Non-invasive risk assessment for the presence of
varices should be applied for stratification (thrombocyte count or
Baveno VI).
Endoscopic retrograde cholangiography (ERC) for dilatation or
stent replacement in patients after liver transplantation or pa-
tients with primary sclerosing cholangitis should be performed
after careful individual risk-benefit considerations, including risk
for nosocomial SARS-CoV-2 infection depending on local COVID-
19 burden.
Patients with COVID-19: Endoscopic procedures are associated
with an increased risk of disseminating SARS-CoV-2. During EGD
or ERC, spreading of virus-containing droplets can occur. In
addition, shedding of the virus in the faeces increases the risk of
dissemination during colonoscopy. Thus, indications forJHEP Reports 2020endoscopic procedures in patients with COVID-19 should be
limited to emergencies such as gastrointestinal bleeding, bacte-
rial cholangitis or other life-threatening conditions.Ultrasound (HCC surveillance)
Patients without COVID-19: HCC surveillance can be deferred
based on available resources (including availability of thera-
peutic options in case of HCC diagnosis) at the centre and the
individual risk assessment. Patients with increased risk, such as
patients with elevated alpha-fetoprotein levels, advanced
cirrhosis, chronic hepatitis B, NASH/diabetes etc., may be priori-
tised if resources are limited.
Patients with COVID-19: HCC surveillance should be deferred
until after recovery.Liver biopsy
Patients without COVID-19: Recommendations strongly depend
on the local COVID-19 burden and the individual indication for
histological assessment.
Biopsy should be deferred in patients with
 NAFLD or chronic viral hepatitis (for grading/staging)
 mildly elevated transaminases (e.g. ALT <3× the upper limit
of normal [ULN]) of unknown aetiology
Biopsy should be performed in patients with
 strongly elevated transaminases (e.g. ALT >5× ULN) of un-
known aetiology (in case of suspected autoimmune
liver disease, treatment without histological diagnosis can
be considered based on individual risk-benefit
considerations)
 liver masses suspicious of malignancy
Patients with COVID-19: Liver biopsy should be deferred in
most patients as
 treatment/care for COVID-19 outweighs diagnosis of co-
existing liver disease
 systemic inflammation associated with COVID-19 will
obscure aetiology-specific histologic characteristics
 liver biopsy may represent a risk for viral transmission
(although the virus has so far not been detected in liver
tissue, the expression of its receptor on cholangiocytes
suggests that the virus might be present in the liver as
well).Collaboration with local health care providers and
primary care physicians
The necessity to reduce travel and limit visits to specialised
centres is a challenge for liver disease patients and local health
care providers alike. In order to facilitate decentralised care
for these patients, close collaborations between specialised
hepatologists and local health care providers is required. This
pertains to several factors such as communication of immu-
nosuppressive target levels in patients after liver trans-
plantation, management of patients with severe ALT elevations
of unknown aetiologies and others. Thus, we recommend that
specialised centres provide easily accessible contact informa-
tion for local health care providers to facilitate fast and un-
complicated collaboration for the benefit of patients with liver
diseases.4vol. 2 j 100113
Table 1. Selected repurposed drugs that have been suggested/discussed for the treatment of COVID-19 and considerations for patients with liver disease or
after liver transplantation.
Drug Mechanism of action, rationale for COVID-19 Considerations for patients with liver
diseases or after liver transplantation
Remdesivir  NUC/viral RNA polymerase inhibitor
(completed phase III for Ebola treatment)
 Inhibits SARS-CoV-2 in vitro24
 Case reports with COVID-1926
 No relevant drug-interactions expected34
 No experience in liver cirrhosis but a NUC might be safer than other drug
classes based on experience with NUCs in chronic hepatitis B and C
 Liver toxicity ([ALT) possible
Chloroquine/
Hydroxychloroquine35
±
azithromycin
 Interference with the cellular receptor ACE224
 Endosomal acidification fusion inhibitor
 Generally used for treatment of malaria and
amoebiasis
 In vitro and in vivo data32,36
 Exclude G6PD deficiency before application
 Drug-interactions with immunosuppressive
drugs: close monitoring of drug level is required
for cyclosporine, tacrolimus, sirolimus,
everolimus34
 Hydroxychloroquine therapy has not been associated with ALT abnormal-
ities and is an extremely rare cause of clinically apparent acute liver injury
(LiverTox).
Lopinavir/ritonavir  Lopinavir/ritonavir are approved PIs for HIV
 In vitro data, experience in patients
with SARS, case reports with COVID-1937
 No proven efficacy in vivo in severe COVID-1928
 Many centres have discontinued its use
 Known and well-studied drug-interactions with immunosuppressive
drugs. mTOR inhibitors (sirolimus, everolimus) should not be co-
administered, close monitoring of drug level are required for calcineurin-
inhibitors (cyclosporin, tacrolimus)34
 Data for patients with liver cirrhosis exist38
 The risk of lopinavir-associated hepatotoxicity in patients with very
advanced liver disease is low
 Based on experience with PIs in HCV, patients with decompensated
cirrhosis should not be treated
Tocilizumab  Humanised mAb targeting interleukin-6 receptor
 Treat cytokine release syndrome observed
in COVID-197
 ALT elevations are frequent but clinically
apparent liver injury with jaundice seem to be rare39
 Patients with decompensated cirrhosis should not be treated
 Consider risk of HBV reactivation40
Methylprednisolone
(steroids)
 Corticosteroids bind nuclear receptors to
dampen proinflammatory cytokines
 Mostly used in patients with septic shock
 Currently NOT recommended by WHO41
 The risk of other infections (e.g. SBP) and viral shedding may increase in
patents with decompensated liver cirrhosis
 Consider antimicrobial prophylaxis
 Consider risk of HBV reactivation
Convalescent plasma  Case reports with COVID-1942  No experience in patients with chronic liver disease
Umifenovir (Arbidol)*  May inhibit viral entry into target cells
and stimulate the immune response,
used to treat influenza in some countries31
 Possible drug interactions between arbidol and CYP3A4 inhibitors and
inducers43
 Potentially metabolised in liver and intestines in humans. Caution in pa-
tients with liver cirrhosis
Favipiravir/favilavir*  Guanine analogue, RNA-dependent RNA poly-
merase
(RdRp)- inhibitor, approved for influenza in
Japan
 Preliminary results from a study with
80 COVID-19 patients31
 Metabolised by aldehyde oxidase and xanthine oxidase. CYP450 iso-
enzymes are not involved in the metabolism
 Elevation of ALT and AST possible.
 No data in cirrhosis available
Sofosbuvir*
maybe combination
with ribavirin
 Nucleotide analogue, RdRp-inhibitor
 Approved for treatment of chronic hepatitis C
 In vitro data show binding to SARS-CoV-2 RdRp44
 Good experience in patients with chronic hepatitis
C including patients with decompensated
cirrhosis
 For drug-interaction details see45
 Ribavirin may cause severe haemolytic anaemia
Baricitinib*  Janus kinase inhibitor, might interrupt endocy-
tosis
of the virus and intracellular assembly of virus
particles46
 Could affect both inflammation and cellular viral
entry
 Associated with transient and usually mild elevations of ALT47
 Patients with decompensated cirrhosis should not be treated
Camostat*  Blocks serine protease TMPRSS2 in vitro which is
required for S protein priming48
 Licensed in Japan for treatment of chronic
pancreatitis
 Patients with chronic viral hepatitis and cirrhosis are excluded from clinical
trial for chronic pancreatitis.49
 Drug-interactions unknown
(continued on next page)
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Table 1 (continued)
Drug Mechanism of action, rationale for COVID-19 Considerations for patients with liver
diseases or after liver transplantation
Emapalumab*  mAb targeting interferon-gamma
 Treat cytokine release syndrome observed
in COVID-197
 Approved for haemophagocytic
lymphohistiocytosis
 Clinical trial for COVID-19 planned50
 Associated with mild and transient ALT elevations typically arising a few
weeks after start of treatment
 Risk of reactivation of tuberculosis, pneumocystis jirovecii, herpes zoster
 Risk of HBV reactivation may be lower
Anakinra*  Interleukin 1 receptor antagonist
 Clinical trial for COVID-19 planned50
 Minimal hepatic metabolism
This list is not intended to give treatment recommendations. The evidence to use these drugs is low. Multiple RCTs for the above-mentioned drugs and some other drugs are
ongoing in patients with SARS-CoV-2 infection.
ACE2, angiotensin-converting enzyme 2; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 2019; NUC, nucleoside analogue; PIs,
protease inhibitors; RdRp, RNA-dependent RNA polymerase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
*These drugs are listed to include the most frequently discussed agents for COVID-19. These drugs may lack clinical efficacy, and some have been considered based on in vitro
observations or their mode of action.
ReviewInpatient care
Many patients with chronic liver disease will continue to require
inpatient care during the COVID-19 crisis for decompensation,
cholangitis, rejection or other complications. General measures
to prevent SARS-CoV-2 exposure and infection will be of utmost
importance for these patients. Depending on the local infra-
structure, implementation of COVID-19-clean wards or hospitals
is warranted. However, based on the local COVID-19-burden, a
sharp separation of “clean” and “dirty” wards/hospitals may not
be sustainable, although recent evidence provides somewhat
reassuring data regarding the absence of environmental
contamination with SARS-CoV-2 RNA of inanimate surfaces
outside patient rooms.20 Wherever possible, patients with
chronic liver disease requiring inpatient care for non-COVID-19
causes should be admitted to COVID-19-clean wards or hospi-
tals. As these institutions may not be able to provide specialised
hepatology-care, similar to our recommendations on outpatient
care, we recommend that specialised centres provide easily
accessible contact information to facilitate immediate hepatol-
ogy consultations.
However, due to the contagiousness of the virus, patients
with underlying liver disease will become infected and will
subsequently require inpatient care for COVID-19. With regards
to nosocomial-infections, recent observations from Spain that
compared patient characteristics between patients with
community-acquired influenza and nosocomial-acquired influ-
enza could not detect a significant difference between these
cohorts with regards to underlying chronic liver disease.21
Whether these observations will also hold up in the context of
the COVID-19 pandemic remains to be proven. Until further ev-
idence emerges, we recommend that patients with chronic liver
disease and COVID-19 are admitted for inpatient care if they have
additional risk factors for a more severe COVID-19 course like
hypertension, diabetes or obesity, cirrhosis, HCC or a post-
transplant status.Treatment considerations for COVID-19
Although there are currently no drugs approved for SARS-CoV-2,
several repurposed drugs have been tested in recent weeks and
many of them are still under investigation (see Table 1).22
Remdesivir acts as an adenosine-analogue that induces RNA
chain termination and was initially developed as an antiviral
agent against Ebola.23 It has recently been shown to inhibit a
clinical isolate of SARS-CoV-2 in vitro24 and to reduce diseaseJHEP Reports 2020severity of the related MERS-CoV-infection in a non-human
primate model in vivo.25 In addition, several reports have sug-
gested clinical efficacy in patients suffering from COVID-19.26,27
Clinical trials are ongoing to further evaluate efficacy in
affected patients. Although ritonavir-boosted lopinavir showed
some antiviral effect on SARS-CoV-2 in vitro, a recently published
clinical trial in patients with severe COVID-19 showed no effect
in vivo compared to no treatment.28 Other drugs currently
under evaluation include chloroquine phosphate or hydroxy-
chloroquine.29 Chloroquine has shown antiviral efficacy against
SARS-CoV-2 in vitro through interference with the ACE2-receptor
mediated endocytosis and is widely used in the treatment of
patients with severe COVID-19 as monotherapy, but also in
combination with azithromycin.24,30–32 The administration of
any of these compounds to infected patients will remain an in-
dividual decision as efficacy and optimal timing remain to be
clarified. However, with regards to patients with chronic liver
disease, possible adverse events have to be kept in mind. This is
particularly important with respect to drug-interactions in pa-
tients with certain immunosuppressive therapies where drug
levels of cyclosporine, tacrolimus, sirolimus or everolimus will
have to be closely monitored. In addition, patients with impaired
liver function are at high risk of drug toxicities, i.e. in patients
with Child-Pugh B/C cirrhosis. Table 1 summarises some con-
siderations with regards to potential toxicities in these patients.
It is also important to stress that all the drugs currently under
investigation are not approved for SARS-CoV-2. However, given
that early initiation of antiviral therapy is known to blunt the
course of influenza, it is reasonable to assume that early treat-
ment initiation might also be beneficial to prevent severe
pneumonia in COVID-19. Thus, in patients with liver disease and
risk factors for a severe course of the disease, we recommend
inclusion into early antiviral treatment programmes or clinical
trials that might be active at different centres.General considerations for patients with chronic liver disease
and COVID-19
 Consider early admission according to the presence of
additional risk factors and inclusion in clinical trials and
(experimental) antiviral therapy of COVID-19 following local
guidelines (see Table 1 for guidance with regards to CLD)
 Prevent acetaminophen overdosing (2–3 g/day is considered
safe in patients with cirrhosis without active alcohol
consumption33)6vol. 2 j 100113
 Do not administer non-steroidal anti-inflammatory drugs in
patients with cirrhosis and portal hypertension33
 See also section on “liver-related diagnostic procedures” for
recommendations on endoscopy, HCC surveillance and liver
biopsySpecific considerations for patients with chronic liver disease
and COVID-19
 In patients with decompensated cirrhosis, treatment for
cirrhosis-associated complications such as portal hypertension,JHEP Reports 2020ascites, hepatic encephalopathy, spontaneous bacterial perito-
nitis etc. should be continued.
 In patients with HCC, locoregional therapies should be
postponed whenever possible and immune-checkpoint
inhibitor therapy temporarily withdrawn. The decision
on whether to continue (reduced dose) kinase inhibitors in
non-severe COVID-19 should be taken on a case-by-case
basis.
 In patients after liver transplantation, dose adjustment of
calceurin- and/or mTOR- inhibitors might be required
depending on the antiviral therapy initiated (Table 1).Abbreviations
ACE2, angiotensin-converting enzyme 2; ACE-I, angiotensin-converting
enzyme inhibitor; ACLF, acute-on-chronic liver failure; ALT, alanine
aminotransferase; AST, aspartate aminotransferase; COVID-19, corona-
virus disease 2019; EGD, esophagogastroduodenoscopy; ERC, endo-
scopic retrograde cholangiography; HCC, hepatocellular carcinoma;
MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty
liver disease; NASH, non-alcoholic steatohepatitis; NUC, nucleoside
analogue; PIs, protease inhibitors; RdRp, RNA-dependent RNA poly-
merase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2;
ULN, upper limit of normal.
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